MedTrace Logo

CliniMACS® CD34+ Reagent System for Expanded Access Use

NCT02026934 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-11-21

No results posted yet for this study

Summary

CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein. The participant will be infused with the CD34+ selected cells in the hopes that it will help the participant engraft. Engraftment is when transplanted stem cells resume production of healthy blood cells.

Conditions

  • Graft-Versus-Host Disease(GVHD)
  • Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells
  • Graft Failure
  • Delayed Graft Function

Interventions

DEVICE

CliniMACS CD34 Reagent System

Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.

Sponsors & Collaborators

  • Miltenyi Biomedicine GmbH

    collaborator INDUSTRY

  • Joseph Antin

    lead OTHER

Principal Investigators

  • Sarah Nikiforow, MD, PhD · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02026934 on ClinicalTrials.gov